EICHORCondition: Idiopathic Pulmonary Fibrosis (IPF) · Sponsor: Vicore Pharma AB
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| UAB Hospital, School of Medicine/Lung Health Center | Birmingham, Alabama, United States | — |
| Keck Medicine of University of Southern California | Los Angeles, California, United States | — |
| Paradigm Clinical Research Centers, Inc. | Redding, California, United States | — |
| UC Davis Health System | Sacramento, California, United States | — |
| UC San Diego Medical Center - Hillcrest | San Diego, California, United States | — |
| Paradigm Clinical Research | San Diego, California, United States | — |
| National Jewish Medical and Research Center | Denver, Colorado, United States | — |
| University of Florida Health (UF Health) | Gainesville, Florida, United States | — |
| Clinical Research Specialists | Kissimmee, Florida, United States | — |
| Emory Saint Joseph's Hospital | Atlanta, Georgia, United States | — |
| Endeavor Health - Evanston Hospital | Evanston, Illinois, United States | — |
| University of Kansas Medical Center | Kansas City, Kansas, United States | — |
+ 99 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06588686